EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

Paolo Sportoletti, Luca Laurenti iD, Annalisa Chiarenza, Gianluca Gaidano, Elisa Albi, Francesca Romana Mauro, Livio Trentin iD, Daniele Vallisa, Fabrizio Pane, Antonio Cuneo iD, Francesco Albano iD, Giulia Zamprogna und 9 weitere

Hematological Oncology · 2024-01 · 42 (1)

DOI: 10.1002/hon.3216 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Hematological Oncology, online erschienen am 29.09.2023. Verfasst von Paolo Sportoletti und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie srl.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) therapies differ in efficacy, side effects, route, frequency, and duration of administration. We assessed patient preferences for treatment attributes and evaluated associations with disease stage, treatment line, and socio‐demographic characteristics in a cross sectional, observational study conducted at 16 Italian hematology centers. Study visits occurred between February and July 2020; 401 adult patients with CLL (201 Watch and Wait (W&W), 200 treated) participated in a discrete choice experiment (DCE), composed of 8 choices between pairs of treatment profiles with different levels of 5 attributes of currently available CLL treatments (length of response, route and duration of administration, risk of side effects including diarrhea, infections, or organ damage). Health‐related quality of life was assessed with the EQ‐5D‐5L, EORTC QLQ‐C30 and QLQ CLL‐16. Previously treated patients had longer disease duration (7 vs. 5 years), higher prevalence of serious comorbidities (45.5% vs. 36.2%) and high‐risk molecular markers (unmutated IGHV 55.6% vs. 17.1%; TP53 mutation 15.2% vs. 4.0%). Health‐related quality of life scores were similar between groups. In the DCE, W&W patients rated “possible occurrence of infections” highest (relative importance [RI] = 36.2%), followed by “treatment and relevant duration” (RI = 28.0%) and “progression‐free survival (PFS)” (RI = 16.9%). Previously treated patients rated “treatment and relevant duration” highest (RI = 33.3%), followed by “possible occurrence of infections” (RI = 28.8%), “possible occurrence of organ damage” (RI = 19.4%), and “PFS” (RI = 9.8%). Concern over infection was rated highest overall; unexpectedly PFS was not among the most important criteria in either group, suggesting that the first COVID‐19 pandemic wave may have influenced patient preferences and concerns about CLL therapy options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAdultHumansPatient PreferenceQuality of LifeCross-Sectional StudiesPandemics

Stichwörter der Autor:innen

chronic lymphocytic leukemiadiscrete choice experimenthealth-related quality of lifetreatment preferences

Autor:innen und Institutionen

  • Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
  • Hematology Institute, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Division of Hematology, Ferrarotto Hospital, Catania, Italy.
  • Division of Haematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.
  • Strategic Research Programme in CLL, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
  • Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.

ORCID-Profile: Luca Laurenti, Livio Trentin, Antonio Cuneo, Francesco Albano, Giuliana Gualberti, Stefano Molica

Förderung

  • AbbVie srl

Zitieren

APA

Sportoletti, P., Laurenti, L., Chiarenza, A., Gaidano, G., Albi, E., Mauro, F. R., Trentin, L., Vallisa, D., Pane, F., Cuneo, A., Albano, F., Zamprogna, G., Coscia, M., Gozzetti, A., Reda, G., Caira, M., Finsinger, P., Gualberti, G., Iannella, E., …, & Molica, S. (2024). Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. Hematological Oncology, 42(1). https://doi.org/10.1002/hon.3216

Vancouver

Sportoletti P, Laurenti L, Chiarenza A, Gaidano G, Albi E, Mauro FR, et al. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. Hematological Oncology. 2024;42(1). doi:10.1002/hon.3216

BibTeX
@article{Sportoletti2024,
  author = {Sportoletti, Paolo and Laurenti, Luca and Chiarenza, Annalisa and Gaidano, Gianluca and Albi, Elisa and Mauro, Francesca Romana and Trentin, Livio and Vallisa, Daniele and Pane, Fabrizio and Cuneo, Antonio and Albano, Francesco and Zamprogna, Giulia and Coscia, Marta and Gozzetti, Alessandro and Reda, Gianluigi and Caira, Morena and Finsinger, Paola and Gualberti, Giuliana and Iannella, Emilia and Malgieri, Simona and Molica, Stefano},
  title = {Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study},
  journal = {Hematological Oncology},
  year = {2024},
  volume = {42},
  number = {1},
  doi = {10.1002/hon.3216}
}
Kostenlos starten →